stock

This article summarizes the most significant insider buying and selling activities reported for US stocks on Monday, February 10, 2025.

Top Insider Buys:

Oncocyte Corp (NASDAQ: OCX ):

Broadwood Partners, L.P. significantly increased its stake in Oncocyte Corp, a $34.6 million market cap company. The firm acquired a total of 5,165,695 shares through two transactions. The first involved purchasing 660,207 shares at $2.05 per share in a registered direct offering, totaling approximately $1.35 million. The second, larger transaction consisted of 4,505,488 shares at the same price, amounting to roughly $9.24 million, conducted through a private placement agreement. Analysts have set price targets ranging from $4.00 to $4.25 for OCX, suggesting potential upside from current levels.

Mach Natural Resources LP (NASDAQ:MNR):

BCE-Mach Aggregator LLC invested approximately $79.9 million in Mach Natural Resources LP by purchasing 5,161,290 common units at $15.50 per unit. This investment comes as MNR, valued at $1.66 billion, offers an attractive dividend yield of ~15%. The purchase increases BCE-Mach Aggregator's holdings to 74,287,410 shares, reflecting a strategic commitment to the crude petroleum and natural gas sector. William W. McMullen, Managing Partner of Bayou City Energy Management, plays a key role in this transaction, although he disclaims beneficial ownership beyond his pecuniary interest.

Alset Inc. (NASDAQ: AEI ):

Chan Heng Fai Ambrose, CEO of Alset Inc., acquired 291,060 shares over two days at average prices of $0.99 and $1.03. The total value of these acquisitions amounts to approximately $294,149. Following these transactions, Ambrose now directly owns 6,329,498 shares, with an additional 319,000 shares held indirectly through HFE Holdings Limited. This increases his beneficial ownership to 6,648,498 shares, highlighting his continued confidence in the company's prospects.

Sionna Therapeutics , Inc. (NASDAQ: SION ):

RA Capital Management purchased 1,124,000 shares of Sionna Therapeutics at $18 per share, totaling $20.25 million. The stock currently trades at $22.24, representing a 23.6% premium to RA Capital's purchase price. Additionally, OrbiMed Advisors LLC, a director at Sionna Therapeutics, acquired 550,000 shares at $18 per share, amounting to $9.9 million. OrbiMed also converted shares of Series B and Series C convertible preferred stock into common stock as part of the company's IPO process.

Top Insider Sells:

Amgen Inc . (NASDAQ: AMGN ):

Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc., sold 25,045 shares at an average price of $293.12, generating approximately $7.34 million. Graham also exercised stock options to acquire the same number of shares at $156.35 per share, which were set to expire on May 3, 2026.

Arista Networks , Inc. (NYSE: ANET ):

Kenneth Duda, Chief Technology Officer and Senior Vice President of Software (ETR: SOWGn ) Engineering, sold shares totaling approximately $9.25 million. The transactions took place at prices ranging from $114.02 to $117.14 per share. These sales were conducted under a Rule 10b5-1 trading plan.

Ares Management Corp (NYSE: ARES ):

Kipp deVeer, Co-President of Ares Management Corp, sold 79,933 shares worth approximately $14.9 million. The shares were sold at prices ranging from $187.08 to $191.58 each. Following these transactions, deVeer holds 1,150,000 restricted units set to vest in installments under an equity incentive plan.

Tesla, Inc. (NASDAQ: TSLA ):

Kimbal Musk, a director at Tesla, sold 74,077 shares at prices between $367.868 and $368.43 per share, totaling approximately $27.6 million. Following these transactions, Musk retains ownership of 1,463,220 shares of Tesla.

Meta Platforms, Inc. (NASDAQ: META ):

Mark Zuckerberg, Chairman and CEO of Meta Platforms, sold shares worth approximately $39.7 million. The sales were executed through two entities: CZI Holdings, LLC, and the Chan Zuckerberg Initiative Foundation, with prices ranging from $712.36 to $724.28 per share.

Investors should stay tuned to insider buying and selling activities as they can provide valuable insights into a company's prospects. While insider transactions alone should not be the sole basis for investment decisions, they can offer clues about management's confidence in the company's future performance and potential upcoming developments. However, it's essential to consider these transactions in the context of broader market trends, company fundamentals, and individual investment goals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.